These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10492157)

  • 21. A comparison of lansoprazole, omeprazole, and ranitidine for reducing preoperative gastric secretion in adult patients undergoing elective surgery.
    Nishina K; Mikawa K; Maekawa N; Takao Y; Shiga M; Obara H
    Anesth Analg; 1996 Apr; 82(4):832-6. PubMed ID: 8615506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.
    Dilger K; Zheng Z; Klotz U
    Br J Clin Pharmacol; 1999 Sep; 48(3):438-44. PubMed ID: 10510158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lansoprazole and ethanol metabolism: comparison with omeprazole and cimetidine.
    Battiston L; Tulissi P; Moretti M; Pozzato G
    Pharmacol Toxicol; 1997 Dec; 81(6):247-52. PubMed ID: 9444664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
    Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
    J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group.
    Lanza F; Goff J; Scowcroft C; Jennings D; Greski-Rose P
    Am J Gastroenterol; 1994 Aug; 89(8):1191-200. PubMed ID: 8053433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lansoprazole: a proton pump inhibitor.
    Garnett WR
    Ann Pharmacother; 1996 Dec; 30(12):1425-36. PubMed ID: 8968456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
    Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
    Russo A; Dattilo M
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):312-9. PubMed ID: 9476183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Knigge K; Fennerty MB
    Ann Intern Med; 1998 Oct; 129(7):547-50. PubMed ID: 9758575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of proton pump inhibitors on thyroid hormone metabolism in rats: a comparison of UDP-glucuronyltransferase induction.
    Masubuchi N; Hakusui H; Okazaki O
    Biochem Pharmacol; 1997 Dec; 54(11):1225-31. PubMed ID: 9416973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lansoprazole and omeprazole in the treatment of acid peptic disorders.
    Blum RA
    Am J Health Syst Pharm; 1996 Jun; 53(12):1401-15. PubMed ID: 8781686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer.
    Lazzaroni M; Bargiggia S; Bianchi Porro G
    Am J Gastroenterol; 1997 Apr; 92(4):649-52. PubMed ID: 9128316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole.
    Sharma VK
    Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S18-21. PubMed ID: 10597120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does the depth of gastric ulceration influence a modified dual therapy with amoxicillin and lansoprazole for Helicobacter pylori-associated gastric ulcer?
    Okai T; Ohtsubo K; Sakai J; Watanabe H; Motoo Y; Kawashima A; Sawabu N
    Can J Gastroenterol; 2000 Oct; 14(9):761-6. PubMed ID: 11064311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.
    Miwa H; Yamada T; Sato K; Ohta K; Ohkura R; Murai T; Nagahara A; Takei Y; Ogihara T; Sato N
    Dig Dis Sci; 2000 Jan; 45(1):77-82. PubMed ID: 10695617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bactericidal activity of lansoprazole and omeprazole against Helicobacter pylori in vitro.
    Vogt K; Hahn H
    Arzneimittelforschung; 1998 Jun; 48(6):694-7. PubMed ID: 9689430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers.
    Sasakii M; Joh T; Yokoyama Y; Seno K; Tsuchida K; Kurokawa T; Itoh M
    J Pharm Pharmacol; 1999 Jul; 51(7):825-30. PubMed ID: 10467958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of omeprazole- versus lansoprazole-based triple therapy for Helicobacter pylori eradication.
    Niv Y
    Dig Dis Sci; 2005 May; 50(5):839-41. PubMed ID: 15906754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.